Form 4: Capricor Director Granted 15,500 Stock Options

Capricor Therapeutics Director Philip J. Gotwals was granted 15,500 stock options with an exercise price of $24.81, vesting monthly through 2026.

Summary

• Philip J. Gotwals, a Director of Capricor Therapeutics, Inc. (CAPR), was granted 15,500 stock options.
• The stock options have an exercise price of $24.81 per share.
• The earliest transaction date for this grant was January 5, 2026.
• The options will vest at a rate of 1/12th on the first day of each month, commencing February 1, 2026, and will be fully vested by December 31, 2026.
• The expiration date for these stock options is January 5, 2036.
• The award is for annual board service.
• The options are subject to early exercise, meaning they can be exercised prior to vesting, but any shares purchased early will be deemed restricted stock and subject to a repurchase option by the Issuer if the reporting person's service terminates before vesting.

Sentiment

Score: 6

Explanation: The filing reports a routine compensation event for a director, which is generally viewed as neutral to slightly positive as it aligns director interests with shareholder value, without indicating any significant operational or financial changes for the company.

Positives

• The grant of stock options aligns the director's financial interests with the long-term performance and shareholder value of Capricor Therapeutics.

Negatives

• No immediate negative implications are present in this routine compensation filing.

Risks

• If the reporting person elects to early exercise the options and purchase shares prior to vesting, those shares will be deemed restricted stock and subject to a repurchase option in favor of Capricor Therapeutics if the reporting person's service terminates prior to full vesting.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future performance or strategic outlook, focusing solely on an insider's equity compensation.

Industry Context

The grant of stock options to a director is a common practice in the biotechnology and pharmaceutical industry, as well as other sectors, to incentivize long-term commitment and align leadership interests with shareholder returns.

Comparison to Industry Standards

• The grant of stock options as part of annual board service compensation is a standard practice across publicly traded companies, including those in the biotechnology sector like Capricor Therapeutics.
• The vesting schedule, with monthly vesting over a year, is a typical structure designed to retain directors and ensure continued engagement.

Related Party Transactions

• The grant of 15,500 stock options to Philip J. Gotwals, a Director of Capricor Therapeutics, constitutes a related party transaction as it involves compensation provided to a member of the company's board.

Stakeholder Impact

• Shareholders: The grant of options to a director can align the director's interests with those of shareholders, potentially encouraging decisions that enhance long-term stock value.

Key Dates

Recommendation

This Form 4 reports a routine grant of stock options to a director as part of their annual compensation. It does not provide new information that would significantly alter the investment thesis for Capricor Therapeutics, thus a 'hold' recommendation remains appropriate based solely on this filing.

Keywords

Capricor Therapeutics, CAPR, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Corporate Governance